Colon Cancer Clinical Trial
Official title:
A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors
Background:
- The experimental cancer treatment drug AZD6244 has been shown to block signals that tell
cancer cells to grow. Cetuximab, a drug approved to treat cancer of the head, neck, colon,
and rectum, also blocks signals that tell cancer cells to grow. Researchers are investigating
the highest safe dose of AZD6244 to give with cetuximab, and will also investigate the
effectiveness of this drug combination in individuals who have colorectal cancer that
involves a particular protein known as the K-RAS protein. Cetuximab is not used to treat
colorectal cancer with K-RAS tumors because it has not been shown to be effective, but
researchers believe that adding AZD6244 to cetuximab may improve how well cetuximab works,
even in people with K-RAS tumors.
Objectives:
- To evaluate the safety and effectiveness of AZD6244 in combination with cetuximab for
solid tumors that have not responded to standard treatment.
- To evaluate the safety and effectiveness of AZD6244 in combination with cetuximab for
colorectal cancer that involves the K-RAS protein and has not responded to standard
treatment.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with solid tumors that have
not responded to standard treatment.
- Individuals at least 18 years of age who have been diagnosed with colorectal cancer that
has not responded to standard treatment.
Design:
- This protocol will involve two separate studies: an initial study to establish the
highest safe and effective dose of AZD6244 and cetuximab in individuals with solid
tumors, and an expansion study of AZD6244 and cetuximab in individuals with colorectal
cancer involving the K-RAS protein.
- Participants will be screened with a full medical history and physical examination,
blood samples, imaging studies, and other tests as required by the researchers.
- AZD6244 is a capsule to be swallowed once or twice a day, every day, with water on an
empty stomach. Cetuximab will be given intravenously once a week, over 2 hours for the
first dose and over an hour for every following dose. This combination of daily AZD6244
and weekly cetuximab will be repeated in 28-day cycles of treatment. Participants will
keep a diary to record the time of taking AZD6244 each day, as well as any side effects.
- Participants will have frequent blood tests and other exams during the first cycle of
treatment, up to five visits to the National Institutes of Health (NIH) and other visits
to their local doctor to in the first 28-day cycle.
- During subsequent cycles, participants will have four visits to NIH and four visits to
your local doctor for examinations, blood tests, and imaging studies.
- Participants may continue to receive the AZD6244 with cetuximab for up to 6 cycles,
until the tumor grows, unacceptable side effects development, or the participant or
participant's doctor decides to stop participation. There will be a final study visit
that repeats the procedures performed during the screening visit....
Background:
- AZD6244 is an oral highly selective and potent uncompetitive inhibitor of
mitogen-activated protein kinase 1/2 (MEK1/2).
- The presence of KRAS mutations predict resistance to EGFR-directed antibody therapy of
metastatic colorectal cancer. This appears secondary to KRAS activation of signaling
cascades downstream of the EGFR receptor, including the RAF/MEK/ERK pathway.
- Our hypothesis is that EGFR inhibition by cetuximab would be augmented in patients with
KRAS mutations if activation of the RAF/MEK/ERK cascade were to be inhibited.
Objectives:
- To determine the dose limiting toxicities and the maximum tolerated dose of AZD6244 in
combination with cetuximab in advanced, refractory solid tumors.
- To assess for evidence of anti-tumor activity with this combination, per tumor
measurements using RECIST criteria.
- To evaluate the pharmacokinetics of AZD6244 and cetuximab when administered
concomitantly.
- To evaluate the safety and tolerability of the combination of AZD6244 and cetuximab in
patients with K-RAS mutated metastatic colorectal cancer.
- To assess the inhibition of the RAF/MEK/ERK pathway in peripheral blood mononuclear
cells secondary to treatment with AZD6244.
- To evaluate the pharmacokinetics of AZD6244 in combination with cetuximab and the
relation to treatment side effects.
Eligibility:
- Patients must have histologically confirmed malignancy that is metastatic or
unresectable and for which standard curative or palliative measures do not exist or are
no longer effective. In the MTD expansion cohort: Patients must have biopsy proven K-RAS
mutant, metastatic colorectal cancer.
- Age greater than or equal to 18
- ECOG performance status less than or equal to 2
Study Design:
- This is a phase 1 dose escalation study of AZD6244 in combination with fixed-dose
cetuximab with an expanded cohort in K-RAS mutated metastatic colorectal cancer.
- Patients will be treated with AZD6244 orally twice daily continuously, and cetuximab
will be administered at standard doses on days 1, 8, 15 and 22. Dose escalations are
outlined per the schema in the parent protocol.
- The dose of AZD6244 will be escalated using a 3-patient cohort design based on first
cycle toxicities until dose limiting toxicities (DLT) and maximum tolerated dose (MTD)
are defined. Once the MTD/RP2D has been identified, an additional 12 patients with K-RAS
mutant colorectal cancer will be enrolled at that dose level, in an effort to more fully
characterize pharmacokinetic characteristics of this combination. If at least an 8%
response rate is observed in the expanded cohort, the combination will be recommended
for future analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |